Dutch biopharma firm Lanthio Pharma has appointed Dr Axel Mescheder as the new chief medical officer of its Lanthipeptide subsidiary MorphoSys.
Dr Mescheder brings over 20 years of research and development experience to the role, and moves from German contract research organisation Medpace, where he served as vice president of European medical and regulatory affairs.
Prior to this, he held the role of chief medical and development officer at both Medigene and TopoTarget, and served as a medical director at MorphoSys.
He has also held a number of research and development management positions at Pfizer’s Centeon, Genetics Institute/Wyeth-Ayerst Research, and Roche.
Dr Heinz Schwer, chief executive officer of Lanthio Pharma, said: “We are very pleased to welcome Axel Mescheder at Lanthio Pharma where he will take a key role in the company’s management.
“We got to know him as an excellent clinical physician and experience research and development manager and we are sure that he will further strengthen and complement our management portfolio.
“Axel’s main focus will be the development of Lanthio Pharma’s lanthipeptide portfolio, in particular the preparation and subsequent executive of the clinical development of MOR107.”